It's hardly conducive to innovation if everyone in an executive group looks the same, is the viewpoint of GN Store Nord, which has laid down the goal that it wants at least 25 percent of senior management positions within the company to be occupied by women by 2025, writes newspaper Børsen.
"Afterwards, we will most certainly raise our ambitions. For many companies, it gets more challenging when you're at more than 20 percent. For us, this is driven by the fact that we're an engineer-heavy company, and that the pond which we're fishing in essentially contains more men than women," says Senior Vice President and Head of HR Group at GN Pierre Berkmann.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
In a world of options, Genmab's CEO chose partnerships
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.
Analyst predicts slow start for Leo Pharma's Adtralza in UK
The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.
US government exercises option to buy Bavarian smallpox vaccines for USD 119m
The first option in an existing contract with the US has been utilized, and Bavarian Nordic can start manufacturing freeze-dried doses of Jynneos for the country in 2023.
Issues at Novo Nordisk lead to shortage of fast-acting diabetes drug
The Danish Medicines Agency has reported that it is currently difficult to find diabetes drug Novorapid in Denmark.
Almirall enters partnership with Inserm Transfert to research vitiligo
A partnership between the Spanish biotech firm and the private subsidy of French public research organization Inserm will focus on finding treatment options for the chronic skin condition vitiligo.
Account Manager 
Clinical Trial Manager 
Director for innovative pre-clinical testing unit 
Nordic Medical Affairs Manager 
Biostatistician 
Senior Manager, Clinical Trial Budget 
SAP System Specialist (Product Supply) – Business Application Services 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Scientific Writer 
Biomarker Operations Lead 
Procurement Process Excellence Specialist 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Communications Consultant 
Client Talent Acquisition Specialist